V-ATPase inhibition overcomes trastuzumab resistance in breast cancer

Molecular Oncology

Volumn 8, Issue 1, 2014, Pages 9-19

  von Schwarzenberg, Karin ^a   Lajtos, Tamás ^b   Simon, Làszló ^b   Müller, Rolf ^c   Vereb, György ^b   Vollmar, Angelika M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Breast cancer; Endocytosis; HER2; Trastuzumab; V ATPase

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; ANTINEOPLASTIC AGENT; ARCHAZOLID; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MUCIN 4; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; TRASTUZUMAB; UNCLASSIFIED DRUG; VACUOLAR PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CANCER SURVIVAL; CARCINOMA CELL; CELL MEMBRANE; CELL SURFACE; CELLULAR DISTRIBUTION; CHROMATIN CONDENSATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOSOL; DRUG TARGETING; ENDOSOME; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

MUS;

BREAST CANCER; ENDOCYTOSIS; HER2; TRASTUZUMAB; V-ATPASE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, SCID; RECEPTOR, ERBB-2; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 84892950507     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.08.011     Document Type: Article

References (41)

1. Austin C.D., De Maziere A.M., Pisacane P.I., van Dijk S.M., Eigenbrot C., Sliwkowski M.X., Klumperman J., Scheller R.H. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell. 2004, 15:5268-5282.
2. Baravalle G., Schober D., Huber M., Bayer N., Murphy R.F., Fuchs R. Transferrin recycling and dextran transport to lysosomes is differentially affected by bafilomycin, nocodazole, and low temperature. Cell. Tissue Res. 2005, 320:99-113.
3. Barok M., Balazs M., Nagy P., Rakosy Z., Treszl A., Toth E., Juhasz I., Park J.W., Isola J., Vereb G., Szollosi J. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett. 2008, 260:198-208.
4. Barok M., Isola J., Palyi-Krekk Z., Nagy P., Juhasz I., Vereb G., Kauraniemi P., Kapanen A., Tanner M., Vereb G., Szollosi J. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther. 2007, 6:2065-2072.
5. Chandarlapaty S., Sakr R.A., Giri D., Patil S., Heguy A., Morrow M., Modi S., Norton L., Rosen N., Hudis C., King T.A. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin. Cancer Res. 2012, 18:6784-6791.
6. Citri A., Gan J., Mosesson Y., Vereb G., Szollosi J., Yarden Y. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep. 2004, 5:1165-1170.
7. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999, 17:2639-2648.
8. Cortese K., Howes M.T., Lundmark R., Tagliatti E., Bagnato P., Petrelli A., Bono M., McMahon H.T., Parton R.G., Tacchetti C. The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments. Mol. Biol. Cell. 2013, 24:129-144.
9. Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat. Rev. Mol. Cell. Biol. 2007, 8:917-929.
10. Harari D., Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000, 19:6102-6114.
11. Hendriks B.S., Opresko L.K., Wiley H.S., Lauffenburger D. Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res. 2003, 63:1130-1137.
12. Hinton A., Bond S., Forgac M. V-ATPase functions in normal and disease processes. Pflugers Arch. 2009, 457:589-598.
13. Hurwitz E., Stancovski I., Sela M., Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. U S A 1995, 92:3353-3357.
14. Huss M., Sasse F., Kunze B., Jansen R., Steinmetz H., Ingenhorst G., Zeeck A., Wieczorek H. Archazolid and apicularen: novel specific V-ATPase inhibitors. BMC Biochem. 2005, 6:13.
15. Karamouzis M.V., Konstantinopoulos P.A., Papavassiliou A.G. Trastuzumab-mechanism of action and use. N. Engl. J. Med. 2007, 357. 1664; author reply 1665-1666.
16. Koninki K., Barok M., Tanner M., Staff S., Pitkanen J., Hemmila P., Ilvesaro J., Isola J. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett. 2010, 294:211-219.
17. Kozik P., Hodson N.A., Sahlender D.A., Simecek N., Soromani C., Wu J., Collinson L.M., Robinson M.S. A human genome-wide screen for regulators of clathrin-coated vesicle formation reveals an unexpected role for the V-ATPase. Nat. Cell. Biol. 2013, 15:50-60.
18. Marshansky V., Futai M. The V-type H+-ATPase in vesicular trafficking: targeting, regulation and function. Curr. Opin. Cell. Biol. 2008, 20:415-426.
19. Mosesson Y., Shtiegman K., Katz M., Zwang Y., Vereb G., Szollosi J., Yarden Y. Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J. Biol. Chem. 2003, 278:21323-21326.
20. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., Hortobagyi G.N., Hung M.C., Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004, 6:117-127.
21. Nagy P., Friedlander E., Tanner M., Kapanen A.I., Carraway K.L., Isola J., Jovin T.M. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005, 65:473-482.
22. Nahta R., Esteva F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006, 8:215.
23. Nahta R., Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006, 232:123-138.
24. Nahta R., Yu D., Hung M.C., Hortobagyi G.N., Esteva F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clinical Practice. Oncol. 2006, 3:269-280.
25. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 1991, 139:271-279.
26. Paris L., Cecchetti S., Spadaro F., Abalsamo L., Lugini L., Pisanu M.E., Iorio E., Natali P.G., Ramoni C., Podo F. Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res. 2010, 12:R27.
27. Pedersen N.M., Breen K., Rodland M.S., Haslekas C., Stang E., Madshus I.H. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2. Mol. Cancer Res. 2009, 7:275-284.
28. Pohlmann P.R., Mayer I.A., Mernaugh R. Resistance to trastuzumab in breast cancer. Clin. Cancer Res. 2009, 15:7479-7491.
29. Presley J.F., Mayor S., McGraw T.E., Dunn K.W., Maxfield F.R. Bafilomycin A1 treatment retards transferrin receptor recycling more than bulk membrane recycling. J. Biol. Chem. 1997, 272:13929-13936.
30. Rasband W.S. ImageJ. U.S. National Institutes of Health 2012, Bethesda, Maryland, USA,. http://imageJ.nih.gov/ij/.
31. Sasse F., Steinmetz H., Hofle G., Reichenbach H. Archazolids, new cytotoxic macrolactones from Archangium gephyra (Myxobacteria). Production, isolation, physico-chemical and biological properties. J. Antibiot. (Tokyo) 2003, 56:520-525.
32. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
33. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
34. Tanner M., Kapanen A.I., Junttila T., Raheem O., Grenman S., Elo J., Elenius K., Isola J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol. Cancer Ther. 2004, 3:1585-1592.
35. Vaccari T., Duchi S., Cortese K., Tacchetti C., Bilder D. The vacuolar ATPase is required for physiological as well as pathological activation of the notch receptor. Development 2010, 137:1825-1832.
36. Wiedmann R.M., von Schwarzenberg K., Palamidessi A., Schreiner L., Kubisch R., Liebl J., Schempp C., Trauner D., Vereb G., Zahler S., Wagner E., Muller R., Scita G., Vollmar A.M. The v-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. Cancer Res. 2012, 72:5976-5987.
37. Wilken J.A., Maihle N.J. Primary trastuzumab resistance: new tricks for an old drug. Ann. N. Y Acad. Sci. 2010, 1210:53-65.
38. Wu Y.C., Wu W.K., Li Y., Yu L., Li Z.J., Wong C.C., Li H.T., Sung J.J., Cho C.H. Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells. Biochem. Biophys. Res. Commun. 2009, 382:451-456.
39. Yang Z., Klionsky D.J. Mammalian autophagy: core molecular machinery and signaling regulation. Curr. Opin. Cell. Biol. 2010, 22:124-131.
40. Zhou X., Agazie Y.M. The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR. Cell Signal 2012, 24:140-150.
41. Zsebik B., Citri A., Isola J., Yarden Y., Szollosi J., Vereb G. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol. Lett. 2006, 104:146-155.